HeartSciences Inc. HSCS
Nov 4, 2026, 10:11 AM EST
- YTD
- -0.16%
- 1 year
- +9.01%
- Market cap
- 15.33M
- Revenue (ttm)
- 18.60K
- EPS (ttm)
- -3.21
- Shares out
- 980.32K
- Forward P/E
- -0.61
- YTD return
- -0.16%
- 1-year return
- +9.01%
- Volume
- 60.63K
- Avg volume
- 163.66K
- Open
- 3.02
- Previous close
- 2.95
- Day's range
- 3.02 – 3.14
- 52-week range
- 1.63 – 5.25
- Beta
- 3.29
- Analysts
- Strong Buy
- Price target
- 13.50 (+337.6%)
- Earnings date
- Sep 12, 2024
6M +1.06 (+52.22%)
Key statistics
- Enterprise value
- 234.37K
- PEG ratio
- 0.00
- Price / sales
- 195.01
- Price / book
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.56M
- Total cash
- 4.34M
- Total debt
- 1.01M
- Return on equity
- -269.29%
- Short % of float
- 6.07%
- 50-day average
- 3.25
- 200-day average
- 5.57
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 13.50
- Target (high)
- 15.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 12, 2024
Expected Sep 12, 2024. Consensus EPS estimate -2.08.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | -2.30 | -2.27 | +0.03 | +1.30% |
| Sep 12, 2024 | Jul 1, 2024 | 0.00 | -2.64 | — | — |
| Sep 12, 2024 | Jul 1, 2024 | 0.00 | — | — | — |
| Jul 29, 2024 | Apr 1, 2024 | 0.00 | 0.00 | — | — |
| Jul 29, 2024 | Apr 1, 2024 | 0.00 | — | — | — |
| Mar 14, 2024 | Jan 1, 2024 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Maxim Group | reit | Buy | Buy |
| Sep 23, 2024 | Ascendiant Capital | reit | Buy | Buy |
| Jan 30, 2023 | Ascendiant Capital | init | — | Buy |
| Dec 19, 2022 | Maxim Group | main | — | Buy |
| Nov 9, 2022 | Maxim Group | init | — | Buy |
| Aug 8, 2022 | Benchmark | init | — | Speculative Buy |
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- heartsciences.com
News
Fortitude Mining Holdings' 15 MW Site In Nebraska Participating In Southwest Power Pool Wholesale Electricity Markets 
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year? 
HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining 
FDA Grants 510(k) Clearance For HeartSciences’ MyoVista wavECGTM Device As 12-Lead Resting Electrocardiograph 
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Why Option Care Health Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket 
Fortitude Appoints Kimberly Pittman as Chief Legal Officer 
HeartSciences Files Prospectus Shelf Registration For $200M Mixed Securities 
HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Your note
Sign in to keep a note on HSCS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HRT Financial LP | 1.04% | 10,166 | 37.61K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.19% | 1,877 | 6.94K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 681 | 2.52K | Sep 29, 2024 |
| Oliver Lagore Vanvalin Investment Group | 0.03% | 305 | 1.13K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 3 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 7 | 25 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.44% | 4,355 | 16.11K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.23% | 2,249 | 8.32K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.20% | 1,916 | 7.09K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.19% | 1,892 | 7.00K | Oct 30, 2024 |